These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8198830)

  • 1. A physiologically based mathematical model of dermal absorption in man.
    Auton TR; Westhead DR; Woollen BH; Scott RC; Wilks MF
    Hum Exp Toxicol; 1994 Jan; 13(1):51-60. PubMed ID: 8198830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling dermal pharmacokinetics using in vitro data. Part II. Fluazifop-butyl in man.
    Auton TR; Ramsey JD; Woollen BH
    Hum Exp Toxicol; 1993 May; 12(3):207-13. PubMed ID: 8100431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of fluazifop-butyl in human volunteers. II: Dermal dosing.
    Ramsey JD; Woollen BH; Auton TR; Batten PL; Leeser JE
    Hum Exp Toxicol; 1992 Jul; 11(4):247-54. PubMed ID: 1354971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does epidermal turnover reduce percutaneous penetration?
    Reddy MB; Guy RH; Bunge AL
    Pharm Res; 2000 Nov; 17(11):1414-9. PubMed ID: 11205736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fate of fluazifop butyl in rat and human skin in vitro.
    Clark NW; Scott RC; Blain PG; Williams FM
    Arch Toxicol; 1993; 67(1):44-8. PubMed ID: 8452479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous absorption and distribution of organophosphates (chlorpyrifos and dichlorvos) following dermal exposure and decontamination scenarios using in vitro human skin model.
    Moore CA; Wilkinson SC; Blain PG; Dunn M; Aust GA; Williams FM
    Toxicol Lett; 2014 Aug; 229(1):66-72. PubMed ID: 24910989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A physiologically based pharmacokinetic model of organophosphate dermal absorption.
    van der Merwe D; Brooks JD; Gehring R; Baynes RE; Monteiro-Riviere NA; Riviere JE
    Toxicol Sci; 2006 Jan; 89(1):188-204. PubMed ID: 16221965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and performance of a spreadsheet-based model for estimating bioavailability of chemicals from dermal exposure.
    Dancik Y; Miller MA; Jaworska J; Kasting GB
    Adv Drug Deliv Rev; 2013 Feb; 65(2):221-36. PubMed ID: 22285584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dislodgeable stratum corneum exfoliation: role in percutaneous penetration?
    Zheng Y; Vieille-Petit A; Chodoutaud S; Maibach HI
    Cutan Ocul Toxicol; 2011 Sep; 30(3):198-204. PubMed ID: 21226557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fate of chemicals in skin after dermal application: does the in vitro skin reservoir affect the estimate of systemic absorption?
    Yourick JJ; Koenig ML; Yourick DL; Bronaugh RL
    Toxicol Appl Pharmacol; 2004 Mar; 195(3):309-20. PubMed ID: 15020193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stratum corneum is an effective barrier to TiO2 and ZnO nanoparticle percutaneous absorption.
    Filipe P; Silva JN; Silva R; Cirne de Castro JL; Marques Gomes M; Alves LC; Santus R; Pinheiro T
    Skin Pharmacol Physiol; 2009; 22(5):266-75. PubMed ID: 19690452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics and control of percutaneous drug absorption in the presence of epidermal turnover.
    Simon L; Goyal A
    J Pharm Sci; 2009 Jan; 98(1):187-204. PubMed ID: 18481307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling dermal pharmacokinetics using in vitro data. Part I. Fluazifop-butyl in the rat.
    Auton TR; Ramsey JD; Woollen BH
    Hum Exp Toxicol; 1993 May; 12(3):199-206. PubMed ID: 8100430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of concentration-time profile and its inter-individual variability following the dermal drug absorption.
    Polak S; Ghobadi C; Mishra H; Ahamadi M; Patel N; Jamei M; Rostami-Hodjegan A
    J Pharm Sci; 2012 Jul; 101(7):2584-95. PubMed ID: 22517028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of physicochemical properties of cyclic terpenes on their ex vivo skin absorption and elimination kinetics.
    Cal K; Kupiec K; Sznitowska M
    J Dermatol Sci; 2006 Feb; 41(2):137-42. PubMed ID: 16260121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of viable skin layers in percutaneous permeation and its implication in mathematical models: theoretical consideration based on parameters for betamethasone 17-valerate.
    Kubota K; Maibach HI
    J Pharm Sci; 1994 Sep; 83(9):1300-6. PubMed ID: 7830247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling of diffusion with partitioning in stratum corneum using a finite element model.
    Barbero AM; Frasch HF
    Ann Biomed Eng; 2005 Sep; 33(9):1281-92. PubMed ID: 16133933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percutaneous penetration and metabolism of 2-butoxyethanol.
    Lockley DJ; Howes D; Williams FM
    Arch Toxicol; 2004 Nov; 78(11):617-28. PubMed ID: 15455191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of epidermal turnover on the dynamics of percutaneous drug absorption.
    Simon L; Kim KS; Kanneganti K
    Math Biosci; 2011 Jan; 229(1):16-21. PubMed ID: 21040736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated human/animal stratum corneum as a partial model for 15 steps in percutaneous absorption: emphasizing decontamination, Part I.
    Hui X; Lamel S; Qiao P; Maibach HI
    J Appl Toxicol; 2013 Mar; 33(3):157-72. PubMed ID: 23112046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.